Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 31Carcinoma, Renal Cell 20Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 11Carcinoma, Hepatocellular 9Brain Neoplasms 8Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Skin Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Mesothelioma 4Kidney Neoplasms 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Sarcoma 3Recurrence 3Multiple Myeloma 3Lymphoma 3Liver Neoplasms 3Gliosarcoma 3Colorectal Neoplasms 3Breast Neoplasms 3Urogenital Neoplasms 2

Interventions

liposomal doxorubicin 1fludarabine 1dostarlimab 1Paclitaxel 1Nivolumab 1Ipilimumab 1Gemcitabine 1Doxorubicin 1Dexamethasone 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Ipilimumab × 90 days × Clear all
NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Brown University

Phase 2 Active not recruiting
46 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡